| Literature DB >> 34346403 |
Neil Gleason1, Pedro A Serrano2, Alejandro Muñoz2, Audrey French3, Sybil Hosek3,4.
Abstract
BACKGROUND: HIV infection rates among sexual minority men and transgender individuals, particularly adolescents and young adults, remain elevated in the United States despite continued improvement in the HIV public health response. However, there remains a knowledge gap in understanding the barriers faced by this community in receiving HIV care and prevention resources. To address this, the Keeping it LITE study was conducted to assess HIV risk factors and barriers to preventive treatment in a large national cohort of young sexual minority men and transgender individuals at high risk of HIV infection.Entities:
Keywords: HIV testing; adolescents and young adults; sexual and gender minorities; social epidemiology
Year: 2021 PMID: 34346403 PMCID: PMC8665391 DOI: 10.2196/30761
Source DB: PubMed Journal: JMIR Form Res ISSN: 2561-326X
Figure 1Examples of advertisements developed for this study.
Characteristics of enrolled participants (N=3444).
| Characteristics | Total (N=3444) | White (n=1813) | Latinx (n=680) | Black (n=417) | Asian or Pacific Islander (n=154) | Other (n=380) | ||||||||
| Age (years), mean (SD) | 24.6 (4.8) | 25.0 (4.8) | 24.2 (4.9) | 24.4 (4.7) | 24.6 (4.8) | 23.7 (4.8) | ||||||||
|
| ||||||||||||||
|
|
| |||||||||||||
|
|
| Gay | 2098 (60.91) | 1165 (64.25) | 416 (61.18) | 227 (54.43) | 100 (64.94) | 190 (50) | ||||||
|
|
| Other | 506 (14.69) | 201 (11.09) | 119 (17.5) | 88 (21.1) | 25 (16.23) | 73 (19.21) | ||||||
|
|
| Straight | 9 (0.26) | 4 (0.22) | 1 (0.15) | 2 (0.48) | 0 (0) | 2 (0.53) | ||||||
|
|
| |||||||||||||
|
|
| Gay | 138 (4) | 54 (2.97) | 29 (4.26) | 34 (8.15) | 4 (2.59) | 17 (4.47) | ||||||
|
|
| Other | 345 (10.02) | 184 (10.15) | 56 (8.23) | 43 (10.31) | 15 (9.74) | 47 (12.37) | ||||||
|
|
| Straight | 5 (0.14) | 0 (0) | 1 (0.15) | 2 (0.48) | 0 (0) | 2 (0.53) | ||||||
|
|
| |||||||||||||
|
|
| Gay | 54 (1.57) | 36 (1.99) | 7 (1.03) | 1 (0.24) | 2 (1.29) | 8 (2.11) | ||||||
|
|
| Other | 213 (6.18) | 129 (7.12) | 33 (4.85) | 10 (2.39) | 8 (5.19) | 33 (8.68) | ||||||
|
|
| Straight | 10 (0.29) | 6 (0.33) | 3 (0.44) | 0 (0) | 0 (0) | 1 (0.26) | ||||||
|
|
| |||||||||||||
|
|
| Gay | 12 (0.35) | 6 (0.33) | 2 (0.29) | 3 (0.72) | 0 (0) | 1 (0.26) | ||||||
|
|
| Other | 44 (1.28) | 28 (1.54) | 7 (1.03) | 5 (1.19) | 0 (0) | 4 (1.05) | ||||||
|
|
| Straight | 10 (0.29) | 0 (0) | 6 (0.88) | 2 (0.48) | 0 (0) | 2 (0.5) | ||||||
|
| ||||||||||||||
|
|
| |||||||||||||
|
|
| Midwest | 1124 (32.64) | 526 (29.01) | 237 (34.85) | 200 (487.96) | 51 (33.12) | 110 (28.95) | ||||||
|
|
| South | 449 (13.04) | 226 (12.46) | 80 (11.76) | 82 (19.66) | 13 (8.44) | 48 (12.63) | ||||||
|
|
| Northeast | 183 (5.31) | 89 (4.91) | 35 (5.15) | 18 (4.32) | 18 (11.69) | 23 (6.05) | ||||||
|
|
| West | 241 (6.99) | 106 (5.85) | 76 (11.18) | 14 (3.36) | 19 (12.34) | 26 (6.84) | ||||||
|
|
| |||||||||||||
|
|
| Midwest | 572 (16.61) | 371 (20.46) | 75 (11.03) | 35 (8.39) | 20 (12.98) | 71 (10.44) | ||||||
|
|
| South | 358 (10.39) | 195 (10.76) | 73 (10.74) | 45 (10.79) | 8 (5.19) | 37 (9.74) | ||||||
|
|
| Northeast | 291 (8.45) | 174 (9.59) | 50 (7.35) | 19 (4.56) | 12 (7.79) | 36 (9.47) | ||||||
|
|
| West | 226 (6.56) | 126 (6.95) | 54 (7.94) | 4 (0.96) | 13 (8.44) | 29 (7.63) | ||||||
|
| ||||||||||||||
|
| HIV negative | 2561 (74.36) | 1388 (76.56) | 507 (74.56) | 258 (61.87) | 117 (75.97) | 291 (76.58) | |||||||
|
| HIV negative and on PrEPc or PEPd | 769 (22.32) | 407 (22.45) | 151 (22.21) | 99 (23.74) | 36 (23.38) | 76 (20) | |||||||
|
| HIV positive | 114 (3.31) | 18 (0.99) | 22 (3.23) | 60 (14.39) | 1 (0.65) | 13 (3.42) | |||||||
|
| ||||||||||||||
|
| Yes | 3208 (93.15) | 1742 (96.08) | 618 (90.88) | 347 (83.21) | 149 (96.75) | 352 (92.63) | |||||||
|
| No | 204 (5.92) | 57 (3.14) | 55 (8.09) | 65 (15.59) | 4 (2.59) | 23 (6.05) | |||||||
|
| ||||||||||||||
|
| ≤Bachelor’s degree | 1548 (44.95) | 899 (49.59) | 276 (42.59) | 141 (33.81) | 95 (61.69) | 137 (36.05) | |||||||
|
| ≥Bachelor’s degree | 1670 (48.49) | 789 (43.52) | 372 (54.71) | 253 (60.67) | 50 (32.48) | 206 (54.21) | |||||||
|
| ||||||||||||||
|
| Insured | 2602 (75.56) | 1423 (78.49) | 501 (73.68) | 278 (66.67) | 129 (83.77) | 271 (71.32) | |||||||
|
| Not Insured | 334 (9.69) | 118 (6.51) | 104 (15.29) | 66 (15.83) | 7 (4.54) | 39 (10.26) | |||||||
|
| ||||||||||||||
|
| Yes | 1937 (56.24) | 1098 (60.56) | 365 (53.68) | 216 (51.79) | 74 (48.05) | 184 (48.42) | |||||||
|
| No | 1026 (29.79) | 457 (25.21) | 236 (34.71) | 155 (37.17) | 43 (27.92) | 135 (35.52) | |||||||
|
| ||||||||||||||
|
| Yes | 2786 (80.89) | 1476 (81.41) | 563 (82.79) | 322 (77.22) | 131 (85.06) | 294 (77.37) | |||||||
|
| No | 436 (12.66) | 215 (11.86) | 86 (12.65) | 72 (17.27) | 14 (9.09) | 49 (12.89) | |||||||
|
| ||||||||||||||
|
| 2 or more | 1241 (36.03) | 584 (32.21) | 256 (37.65) | 208 (49.88) | 51 (33.12) | 142 (37.37) | |||||||
|
| Less than 2 | 2203 (63.96) | 1229 (67.79) | 424 (62.35) | 209 (50.12) | 103 (66.88) | 238 (62.63) | |||||||
|
| ||||||||||||||
|
| Yes | 2972 (86.29) | 1594 (87.92) | 599 (88.09) | 328 (78.66) | 138 (89.61) | 313 (82.37) | |||||||
|
| No | 472 (13.7) | 219 (12.08) | 81 (11.91) | 89 (21.34) | 16 (10.39) | 67 (17.63) | |||||||
|
| ||||||||||||||
|
| Yes | 533 (15.48) | 276 (15.22) | 109 (16.03) | 49 (11.75) | 21 (13.64) | 78 (20.53) | |||||||
|
| No | 2133 (61.93) | 1206 (66.52) | 398 (58.53) | 238 (57.07) | 90 (58.44) | 201 (52.89) | |||||||
aDenotes missing data.
bEHE: ending the HIV epidemic priority jurisdictions [15].
cPrEP: pre-exposure prophylaxis.
dPEP: postexposure prophylaxis.
eRisk criteria: (1) inconsistent condom use, (2) HIV-positive partner, and (3) bacterial sexually transmitted infection in the past 6 months.
fPrEP indication is based on Centers for Disease Control and Prevention’s draft of clinical practice guidelines [16]: HIV negative, recent anal or vaginal sex, and one of the following: inconsistent condom use, HIV-positive partner, or bacterial sexually transmitted infection in past 6 months.
gSubstance use: cocaine, meth, or heroin use in past 6 months.
Figure 2Enrollment activity by study quarter.
Figure 3Map of participant enrollment by location.
Participant characteristics by recruitment method (n=2649).
| Characteristics | Total | Social media | Word-of-mouth | LGBTQ+a apps | Print ads | Social media versus all other, univariate ORb (95% CI) | Multivariate OR (95% CI) | |||||||||||||
| Total, n (%) | 2649 (100) | 1684 (63.61) | 499 (18.81) | 341 (12.91) | 125 (4.61) | —d | — | — | ||||||||||||
|
| 24.6 (4.8) | 24.3 (4.9) | 24.8 (4.6) | 26.6 (4.5) | 23.5 (4.9) | 0.96 (0.94-0.97) | <.001 | 0.97 (0.95-0.98) | ||||||||||||
|
| 30-34 | 483 (18.2) | 282 (16.7) | 85 (17) | 97 (28.4) | 19 (15.2) | Reference |
|
| |||||||||||
|
| 25-29 | 860 (32.5) | 506 (30.0) | 182 (36.5) | 141 (41.3) | 31 (24.8) | 1.02 (0.81-1.28) |
|
| |||||||||||
|
| 20-24 | 858 (32.4) | 570 (33.8) | 162 (32.5) | 77 (22.6) | 49 (39.2) | 1.41 (1.12-1.78) |
|
| |||||||||||
|
| 18-19 | 243 (9.2) | 165 (9.8) | 42 (8.4) | 22 (6.5) | 14 (11.2) | 1.51 (1.09-2.09) |
|
| |||||||||||
|
| 13-17 | 205 (7.7) | 161 (9.6) | 28 (5.6) | 4 (1.2) | 12 (9.6) | 2.61 (1.78-3.81) |
|
| |||||||||||
|
| ||||||||||||||||||||
|
|
| <.001 |
| |||||||||||||||||
|
|
| White | 1091 (41.21) | 725 (43.13) | 168 (33.68) | 154 (45.21) | 44 (35.18) | Reference |
| Reference | ||||||||||
|
|
| Latinx | 434 (16.43) | 276 (16.41) | 71 (14.21) | 68 (19.89) | 19 (15.21) | 0.88 (0.70-1.11) |
| 0.82 (0.63-1.06) | ||||||||||
|
|
| Black | 250 (9.37) | 122 (7.18) | 68 (13.57) | 47 (13.78) | 13 (10.45) | 0.48 (0.36-0.64) |
| 0.58 (0.42-0.80) | ||||||||||
|
|
| Asian | 102 (3.89) | 69 (4.08) | 20 (4.03) | 12 (3.54) | 1 (0.79) | 1.06 (0.68-1.63) |
| 1.06 (0.66-1.69) | ||||||||||
|
|
| Other | 206 (7.78) | 137 (8.12) | 37 (7.42) | 23 (6.71) | 9 (7.21) | 1.00 (0.73-1.37) |
| 1.01 (0.72-1.43) | ||||||||||
|
|
| |||||||||||||||||||
|
|
| White | 297 (11.22) | 199 (11.77) | 66 (13.23) | 15 (4.56) | 17 (13.61) | 1.03 (0.78-1.35) | — | 0.89 (0.66-1.20) | ||||||||||
|
|
| Latinx | 101 (3.81) | 54 (3.21) | 29 (5.79) | 9 (2.61) | 9 (7.22) | 0.58 (0.38-0.87) | — | 0.72 (0.45-1.14) | ||||||||||
|
|
| Black | 67 (2.45) | 35 (2.13) | 23 (4.56) | 3 (0.87) | 6 (4.76) | 0.55 (0.34-0.91) | — | 0.90 (0.52-1.57) | ||||||||||
|
|
| Asian | 20 (0.82) | 12 (0.65) | 2 (0.36) | 6 (1.81) | 0 (0) | 0.76 (0.31-1.87) | — | 0.85 (0.31-2.33) | ||||||||||
|
|
| Other | 81 (3.13) | 55 (3.33) | 15 (3.02) | 4 (1.17) | 7 (5.61) | 1.07 (0.66-1.73) | — | 0.85 (0.50-1.45) | ||||||||||
|
| ||||||||||||||||||||
|
|
| <.001 |
| |||||||||||||||||
|
|
| Midwest | 735 (27.71) | 252 (15.04) | 283 (56.74) | 96 (28.19) | 104 (83.21) | Reference |
| Reference | ||||||||||
|
|
| South | 384 (14.51) | 291 (17.34) | 43 (8.62) | 45 (13.16) | 5 (4.02) | 6.00 (4.54-7.93) |
| 5.96 (4.48-7.92) | ||||||||||
|
|
| Northeast | 150 (5.66) | 110 (6.47) | 18 (3.61) | 19 (5.62) | 3 (2.37) | 5.27 (3.56-7.81) |
| 5.54 (3.71-8.26) | ||||||||||
|
|
| West | 209 (7.92) | 154 (9.12) | 16 (3.18) | 38 (11.11) | 1 (0.77) | 5.37 (3.81-7.57) |
| 5.19 (3.66-7.37) | ||||||||||
|
|
| |||||||||||||||||||
|
|
| Midwest | 429 (16.21) | 295 (17.53) | 68 (13.62) | 60 (17.61) | 6 (4.78) | 4.22 (3.27-5.44) | — | 3.54 (2.72-4.60) | ||||||||||
|
|
| South | 315 (11.87) | 245 (14.45) | 36 (7.21) | 33 (9.72) | 1 (0.76) | 6.71 (4.94-9.11) | — | 6.14 (4.50-8.39) | ||||||||||
|
|
| Northeast | 232 (8.81) | 185 (11.02) | 19 (3.76) | 24 (7.02) | 4 (3.21) | 7.54 (5.29-10.75) | — | 6.56 (4.58-9.41) | ||||||||||
|
|
| West | 195 (7.41) | 152 (9.02) | 16 (3.21) | 26 (7.63) | 1 (0.78) | 6.78 (4.67-9.82) | — | 6.14 (4.20-8.96) | ||||||||||
|
| ||||||||||||||||||||
|
| HIV negative | 1969 (74.3) | 1321 (78.42) | 332 (66.45) | 221 (64.78) | 95 (76.02) | Reference | <.001 | Reference | |||||||||||
|
| PrEPg or PEPh | 586 (22.1) | 320 (19.05) | 144 (28.9) | 99 (29.0) | 23 (18.34) | 0.59 (0.49-0.71) |
| 0.78 (0.63-0.97) | |||||||||||
|
| HIV positive | 94 (3.45) | 43 (2.63) | 23 (4.6) | 21 (6.2) | 7 (5.6) | 0.41 (0.27-0.63) |
| 0.66 (0.40-1.06) | |||||||||||
|
| ||||||||||||||||||||
|
| 2 or more | 989 (37.31) | 558 (33.08) | 234 (46.89) | 160 (46.91) | 37 (29.56) | Reference | <.001 | Reference | |||||||||||
|
| Less than 2 | 1660 (62.72) | 1126 (66.91) | 265 (53.13) | 181 (53.12) | 88 (70.34) | 1.63 (1.38-1.92) | — | 1.19 (0.98-1.45) | |||||||||||
|
| ||||||||||||||||||||
|
| Yes | 2371 (89.45) | 1518 (90.1) | 440 (88.21) | 315 (92.42) | 98 (78.42) | Reference | .16 | — | |||||||||||
|
| No | 278 (10.51) | 166 (9.88) | 59 (11.83) | 26 (7.58) | 27 (21.57) | 0.83 (0.65-1.07) | — | — | |||||||||||
|
| ||||||||||||||||||||
|
| Yes | 416 (20.56) | 253 (15.02) | 81 (20.71) | 62 (24.17) | 20 (20.41) | Reference | .32 | — | |||||||||||
|
| No | 1599 (79.34) | 1015 (60.27) | 311 (79.32) | 195 (75.87) | 78 (79.58) | 1.12 (0.90-1.40) | — | — | |||||||||||
aLGBTQ+: lesbian, gay, bisexual, transgender, and queer.
bOR: odds ratio.
cResults of logistic regression (outcome variable=recruited via social media vs recruited via other method).
dNot available.
eDenotes missing data.
fEHE: ending the HIV epidemic priority jurisdictions [15].
gPrEP: pre-exposure prophylaxis.
hPEP: postexposure prophylaxis.
iRisk criteria: (1) inconsistent condom use, (2) HIV-positive partner, and/or (3) bacterial sexually transmitted infection in the past 6 months.
jPre-exposure prophylaxis indication is based on Centers for Disease Control and Prevention’s draft of clinical practice guidelines [16]: HIV negative, recent anal or vaginal sex, and one of the following: inconsistent condom use, HIV-positive partner, or bacterial sexually transmitted infection in past 6 months.
kSubstance use: cocaine, meth, or heroin use in past 6 months ≥2 risk criteria: (1) inconsistent condom use, (2) HIV-positive partner, and/or (3) bacterial sexually transmitted infection in the past 6 months.
Characteristics of participants by enrollment status (n=11,821).
| Characteristics | Total | Did not qualify | Did not enroll | Enrolled | Enrolled versus did not enroll, univariate ORa (95% CI) | Multivariate OR (95% CI) | |||||||||||||
| Total, n (%) | 11,821 (100) | 6295 (53.25) | 2082 (17.62) | 3444 (29.13) | —c | — | — | ||||||||||||
|
| 25.1 (8.1) | 25.9 (10.0) | 23.6 (4.9) | 24.6 (4.8) | 1.04 (1.03-1.06) | <.001 | 1.02 (1.00-1.03) | ||||||||||||
|
| >34 | 778 (6.6) | 778 (12.4) | 0 (0) | 0 (0) | — |
|
| |||||||||||
|
| 30-34 | 1593 (13.5) | 681 (10.8) | 293 (14.1) | 619 (18) | Reference |
|
| |||||||||||
|
| 25-29 | 2792 (23.6) | 1181 (18.8) | 546 (26.2) | 1065 (30.9) | 0.92 (0.78-1.1) |
|
| |||||||||||
|
| 20-24 | 4017 (34.0) | 2049 (32.5) | 777 (37.3) | 1191 (34.6) | 0.73 (0.61-0.86) |
|
| |||||||||||
|
| 18-19 | 1386 (11.7) | 827 (13.1) | 220 (10.6) | 339 (9.8) | 0.73 (0.59-0.91) |
|
| |||||||||||
|
| 13-17 | 1252 (10.6) | 776 (12.3) | 246 (11.8) | 230 (6.7) | 0.44 (0.35-0.56) |
|
| |||||||||||
|
| <13 | 3 (0) | 3 (0) | 0 (0) | 0 (0) | — |
|
| |||||||||||
|
| |||||||||||||||||||
|
|
| <.001 |
| ||||||||||||||||
|
|
| White | 3726 (31.45) | 1671 (26.48) | 685 (32.88) | 1370 (39.78) | Reference |
| Reference | ||||||||||
|
|
| Latinx | 1405 (11.87) | 514 (8.18) | 355 (17.09) | 536 (15.57) | 0.75 (0.64-0.89) |
| 0.79 (0.67-0.94) | ||||||||||
|
|
| Black | 892 (7.52) | 349 (5.48) | 226 (10.87) | 317 (9.16) | 0.70 (0.58-0.85) |
| 0.66 (0.53-0.81) | ||||||||||
|
|
| Asian | 322 (2.69) | 122 (1.89) | 75 (3.59) | 125 (3.62) | 0.83 (0.62-1.13) |
| 0.85 (0.62-1.17) | ||||||||||
|
|
| Other | 735 (6.16) | 295 (4.68) | 175 (8.36) | 265 (7.66) | 0.76 (0.61-0.94) |
| 0.79 (0.63-0.99) | ||||||||||
|
|
| ||||||||||||||||||
|
|
| White | 2476 (20.87) | 1773 (28.16) | 260 (12.49) | 443 (12.89) | 0.85 (0.71-1.02) | — | 1.12 (0.92-1.36) | ||||||||||
|
|
| Latinx | 737 (6.19) | 473 (7.52) | 120 (5.76) | 144 (4.19) | 0.60 (0.46-0.78) | — | 0.71 (0.54-0.94) | ||||||||||
|
|
| Black | 824 (7.04) | 627 (10.02) | 97 (4.67) | 100 (2.91) | 0.52 (0.38-0.69) | — | 0.60 (0.44-0.82) | ||||||||||
|
|
| Asian | 147 (1.23) | 108 (1.72) | 10 (0.49) | 29 (0.77) | 1.45 (0.70-2.99) | — | 1.85 (0.88-3.85) | ||||||||||
|
|
| Other | 557 (4.72) | 363 (5.77) | 79 (3.8) | 115 (3.31) | 0.73 (0.54-0.98) | — | 0.96 (0.70-1.32) | ||||||||||
|
| |||||||||||||||||||
|
|
| .71 | — | ||||||||||||||||
|
|
| Midwest | 3666 (31.02) | 1893 (30.08) | 649 (31.32) | 1124 (32.6) | Reference |
|
| ||||||||||
|
|
| South | 1487 (12.57) | 769 (12.21) | 269 (13) | 449 (13.03) | 0.96 (0.81-1.15) |
|
| ||||||||||
|
|
| Northeast | 592 (5.02) | 300 (4.79) | 109 (5.29) | 183 (5.31) | 0.97 (0.75-1.25) |
|
| ||||||||||
|
|
| West | 772 (6.52) | 373 (5.89) | 158 (7.62) | 241 (6.8) | 0.88 (0.70-1.10) |
|
| ||||||||||
|
|
| ||||||||||||||||||
|
|
| Midwest | 2431 (20.62) | 1486 (23.61) | 373 (18.01) | 572 (16.56) | 0.89 (0.75-1.04) | — | — | ||||||||||
|
|
| South | 1121 (9.47) | 558 (8.86) | 205 (9.91) | 358 (10.42) | 1.01 (0.83-1.23) | — | — | ||||||||||
|
|
| Northeast | 1011 (8.59) | 559 (8.88) | 161 (7.81) | 291 (8.42) | 1.04 (0.84-1.29) | — | — | ||||||||||
|
|
| West | 730 (6.2) | 356 (5.69) | 148 (7.12) | 226 (6.6) | 0.88 (0.70-1.11) | — | — | ||||||||||
|
| |||||||||||||||||||
|
| HIV negative, not on PrEPf or PEPg | 10,536 (89.12) | 5984 (95.08) | 1991 (95.59) | 2561 (74.36) | Reference | <.001 | Reference | |||||||||||
|
| HIV negative; on PrEP or PEP | 807 (6.82) | 0 (0) | 38 (1.77) | 769 (22.31) | 15.73 (11.3-21.9) | — | 16.42 (11.7-23.05) | |||||||||||
|
| HIV positive | 478 (4.03) | 311 (4.92) | 53 (2.53) | 114 (3.27) | 1.67 (1.20-2.33) | — | 2.25 (1.57-3.2) | |||||||||||
|
| |||||||||||||||||||
|
| 3 | 649 (5.48) | 148 (2.39) | 170 (8.22) | 331 (9.61) | Reference | <.001 | Reference | |||||||||||
|
| 2 | 1868 (15.77) | 539 (8.61) | 419 (20.07) | 910 (26.38) | 1.12 (0.90-1.39) |
| 1.64 (1.28-2.11) | |||||||||||
|
| 1 | 4905 (41.45) | 1876 (29.83) | 1186 (57.03) | 1843 (53.51) | 0.80 (0.65-0.97) |
| 1.55 (1.22-1.96) | |||||||||||
|
| 0 | 4399 (37.23) | 3732 (59.33) | 307 (14.67) | 360 (10.46) | 0.60 (0.47-0.77) |
| 1.4 (1.05-1.88) | |||||||||||
aOR: odds ratio.
bResults of logistic regression (outcome variable=enrolled vs did not enroll).
cNot available.
dDenotes missing data.
eEHE: ending the HIV epidemic priority jurisdictions [15].
fPrEP: pre-exposure prophylaxis.
gPEP: postexposure prophylaxis.
hRisk criteria: (1) inconsistent condom use, (2) HIV-positive partner, and/or (3) bacterial sexually transmitted infection in the past 6 months.
Characteristics of participants using HIV self-testing versus other HIV status verification (n=3444).
| Characteristics | Total | HIV self-test | Other status verification | Univariate ORa (95% CI) | Multivariate OR (95% CI) | ||||||||
| Total, n (%) | 3444 (100) | 2573 (74.71) | 871 (25.29) | —c | — | — | |||||||
|
| 24.6 (4.8) | 24.3 (4.9) | 25.5 (4.4) | 0.95 (0.93-0.96) | <.001 | 1.02 (0.99-1.04) | |||||||
|
| 30-34 | 619 (18.0) | 438 (17.0) | 181 (20.8) | Reference | <.001 |
| ||||||
|
| 25-29 | 1065 (30.9) | 761 (29.6) | 304 (34.9) | 1.03 (0.83-1.29) | — |
| ||||||
|
| 20-24 | 1191 (34.6) | 883 (34.3) | 308 (35.4) | 1.18 (0.95-1.47) | — |
| ||||||
|
| 18-19 | 339 (9.8) | 275 (10.7) | 64 (7.3) | 1.78 (1.29-2.45) | — |
| ||||||
|
| 13-17 | 230 (6.7) | 216 (8.4) | 14 (1.6) | 6.38 (3.61-11.25) | — |
| ||||||
|
| |||||||||||||
|
|
| <.001 |
| ||||||||||
|
|
| White | 1370 (39.78) | 1042 (40.49) | 328 (37.67) | Reference |
| Reference | |||||
|
|
| Latinx | 536 (15.56) | 400 (15.55) | 136 (15.61) | 0.93 (0.74-1.17) |
| 1.09 (0.80-1.48) | |||||
|
|
| Black | 317 (9.2) | 188 (7.31) | 129 (14.83) | 0.46 (0.36-0.59) |
| 0.64 (0.44-0.92) | |||||
|
|
| Asian | 125 (3.63) | 83 (3.23) | 42 (4.82) | 0.62 (0.42-0.92) |
| 0.58 (0.35-1.97) | |||||
|
|
| Other | 265 (7.69) | 197 (7.66) | 68 (7.78) | 0.91 (0.67-1.23) |
| 1.09 (0.72-1.63) | |||||
|
|
| ||||||||||||
|
|
| White | 443 (12.86) | 368 (14.3) | 75 (8.56) | 1.54 (1.17-2.04) | — | 1.00 (0.70-1.43) | |||||
|
|
| Latinx | 144 (4.18) | 115 (4.47) | 29 (3.34) | 1.25 (0.82-1.91) | — | 1.10 (0.63-1.91) | |||||
|
|
| Black | 100 (2.9) | 65 (2.53) | 35 (4.02) | 0.58 (0.38-0.90) | — | 0.53 (0.27-1.04) | |||||
|
|
| Asian | 29 (0.84) | 22 (0.86) | 7 (0.78) | 0.99 (0.42-2.34) | — | 0.42 (0.14-1.26) | |||||
|
|
| Other | 115 (3.34) | 93 (3.61) | 22 (2.45) | 1.33 (0.82-2.15) | — | 0.92 (0.50-1.69) | |||||
|
| |||||||||||||
|
|
| <.001 |
| ||||||||||
|
|
| Midwest | 1124 (32.63) | 801 (31.13) | 323 (37.07) | Reference |
| Reference | |||||
|
|
| South | 449 (13.04) | 329 (12.79) | 120 (13.78) | 1.11 (0.86-1.41) |
| 0.72 (0.52-1.00) | |||||
|
|
| Northeast | 183 (5.31) | 105 (4.08) | 78 (9.03) | 0.54 (0.39-0.75) |
| 0.47 (0.30-0.71) | |||||
|
|
| West | 241 (6.99) | 156 (6.06) | 85 (9.82) | 0.74 (0.55-0.99) |
| 0.44 (0.30-0.65) | |||||
|
|
| ||||||||||||
|
|
| Midwest | 572 (16.61) | 481 (18.69) | 91 (10.39) | 2.13(1.65-2.76) | — | 1.13 (0.81-1.57) | |||||
|
|
| South | 358 (10.39) | 293 (11.39) | 65 (7.47) | 1.82 (1.35-2.45) | — | 1.19 (0.80-1.78) | |||||
|
|
| Northeast | 291 (8.45) | 235 (9.13) | 56 (6.42) | 1.69 (1.23-2.33) | — | 0.96 (0.63-1.45) | |||||
|
|
| West | 226 (6.56) | 173 (6.72) | 53 (6.08) | 1.32 (0.94-1.84) | — | 0.66 (0.43-1.03) | |||||
|
| <.001 | — | |||||||||||
|
| HIV negative | 2561 (74.36) | 2228 (86.59) | 333 (38.18) | Reference |
|
| ||||||
|
| PrEPf or PEPg | 769 (22.33) | 313 (12.16) | 456 (52.36) | 0.10 (0.09-0.12) |
|
| ||||||
|
| HIV positive | 114 (3.31) | 32 (1.24) | 82 (9.34) | 0.06 (0.04-0.09) |
|
| ||||||
|
| <.001 |
| |||||||||||
|
| 2 or more | 1241 (36.03) | 756 (29.38) | 485 (55.73) | Reference |
| Reference | ||||||
|
| Less than 2 | 2203 (63.97) | 1817 (70.62) | 386 (44.34) | 3.02 (2.58-3.54) |
| 1.35 (1.08-1.69) | ||||||
|
| .52 | — | |||||||||||
|
| Yes | 2972 (86.29) | 2226 (86.51) | 746 (85.56) | Reference |
|
| ||||||
|
| No | 472 (13.7) | 347 (13.53) | 125 (14.36) | 0.93 (0.75-1.16) |
|
| ||||||
|
| .003 |
| |||||||||||
|
| Yes | 533 (15.48) | 365 (18.58) | 168 (22.78) | Reference |
| Reference | ||||||
|
| No | 2133 (61.93) | 1597 (81.36) | 536 (76.13) | 1.37 (1.11-1.69) |
| 0.77 (0.60-1.00) | ||||||
aOR: odds ratio.
bResults of logistic regression (outcome variable=HIV self-test vs. other HIV verification).
cNot available.
dDenotes missing data.
eEHE: ending the HIV Epidemic priority jurisdictions [15].
fPrEP: pre-exposure prophylaxis.
gPEP: postexposure prophylaxis.
hRisk criteria: (a) inconsistent condom use, (b) HIV-positive partner, and/or (c) bacterial sexually transmitted infection in the past 6 months.
iPre-exposure prophylaxis indication is based on Centers for Disease Control and Prevention’s draft of clinical practice guidelines [16]: HIV negative, recent anal or vaginal sex, and one of the following: inconsistent condom usage, HIV-positive partner, or bacterial sexually transmitted infection in past 6 months.
jSubstance use: cocaine, meth, or heroin use in past 6 months.